Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To detect the presence of CD133 and CD44 in human CRC specimens and to correlate the level of marker expression with tumor staging.
|
30880758 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two meta-analysis reports have suggested that CD133 expression is significantly associated with shorter survival, and CD133 may play an important role in the progression of colorectal cancer.
|
28190751 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD44 and CD133 mRNA were highly correlatively co-expressed in colorectal cancer with hepatic metastases.
|
25625240 |
2015 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
|
22552364 |
2012 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The findings suggest that CD133 could serve as a predictive marker of poor prognosis and treatment failure in CRC.
|
26840260 |
2016 |
Colorectal Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The study may contribute to the understanding of the role of CD133 inactivation in the progression of colorectal cancers.
|
20593500 |
2010 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Also, cohort evaluation showed that CD133 overexpression at protein level is a marker of poor overall survival in colorectal cancer (CRC) patients.
|
30317669 |
2019 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
By Cox progression analysis, it was shown that CEA/CK/CD133 mRNA in tumor drainage blood was an independent prognostic factor for DFS and OS in patients with Dukes' stage B and C. These results suggest that detecting CEA/CK/CD133 mRNA in tumor drainage blood by the real-time RT-PCR method would have a prognostic value in CRC patients with Dukes' stage B and C.
|
22267181 |
2012 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared to control, the expression of CD133 and ezrin mRNA and protein in CRC were significantly up-regulated (P < 0.05).
|
28261953 |
2017 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of CD133, a cancer stem cell marker, and of the α-subunit of the dystroglycan (α-DG) complex, have been previously reported to be altered in colorectal cancers.
|
22964035 |
2012 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
|
18829568 |
2008 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A CRC patient series was studied for expression of CD133 and other CSC markers by microarray and quantitative PCR analysis.
|
22496204 |
2012 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the current research, CD133 expression in primary CRC was detected by immunohistochemistry, and an asymmetric BiAb consisting of monomer of chimeric AC133 (mouse anti-human CD133 monoclonal antibody) and single chain of humanized OKT3 was developed to eradicate CD133-expressing tumor cells by arming activated T cells in vitro and in vivo.
|
26049545 |
2016 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further investigation of the role of CD133-positive cells in lymph node metastases in CRC is required.
|
26637875 |
2015 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In light of the recent discovery of tumor-initiating cancer stem cells (CSCs) in various tumor types, we developed an in vitro CSC model from xenograft tumors established in mice from a colorectal cancer patient tumor in which the CD133+/EpCAM+ population represented tumor-initiating cells.
|
23826249 |
2013 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Differential expression of CD133 based on microsatellite instability status in human colorectal cancer.
|
23065858 |
2014 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In order to identify other CRC stem cell-specific genes, we performed a comparative expression profiling of CD133(+) and CD133(-) cell populations in primary and metastatic tumors from four patients with CRC.
|
25331798 |
2015 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To accomplish this aim, we use immunohistochemistry (IHC) and double IHC with different potential stem-like markers, anti-musashi (Msi), anti-CD133, anti- LGR5 and anti-ALDH1 to examine the presentation of stem-like cells in different compartments including adenoma/CRC epithelium, transitional crypts and tumor stroma in colorectal adenoma and CRC.
|
28484082 |
2017 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD133 expression is a putative cancer stem cell marker and a proposed prognostic marker in CRC, whereas the predictive value of CD133 expression for effect of adjuvant chemotherapy in CRC is unclear.
|
27435662 |
2016 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Initially the size of the CD133-expressing (CD133+) population in eight well-described CRC cell lines was measured by flow cytometry and was found to range from 0% to >95%.
|
20502714 |
2010 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
After Cox regression, age, Duck's stage, lymph node metastasis, and CD133 and CD44 proteins co-expression were shown to be the independent prognostic factors of colorectal cancers.
|
21764578 |
2012 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The great majority of the cells expressing CD133 also expressed gastrin precursors in both DLD-1 cells, which retain a stem cell-like subpopulation, and human CRC specimens.
|
19321126 |
2009 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review aims to gather the old and most recent data on the prognostic and therapeutic values of CD133 and CD133-targeted therapies in CRC.
|
31579983 |
2020 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133 and CD44 are putative cancer stem cell (CSC) markers in colorectal cancer (CRC).
|
24921913 |
2014 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, these data show that ABCG2 expression correlates with the presence of CD133-positive cancer cells, and thus is a possible therapeutic target for colorectal cancer.
|
27449042 |
2016 |